An Intrapancreatic Accessory Spleen That Was Difficult to Diagnose Due to Temporal Changes after Splenectomy

Daisuke Uchida, Koichiro Tsutsumi, Hironari Kato and Hiroyuki Okada

Abstract:
Accessory spleen (AS) is a common anomaly, and 20% of AS cases occur in the pancreatic tail. An intrapancreatic AS can be difficult to distinguish from pancreatic neoplasms. In most cases, an AS is described as a hypervascular and solitary tumor, but an AS sometimes takes other forms. We herein report a rare case of an intrapancreatic AS with temporal changes in its appearance after splenectomy, which mimicked aspects of pancreatic cancer. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and $^{99m}$Tc sulfur colloid scintigraphy were useful for the diagnosis.

Key words: accessory spleen, EUS-FNA, splenectomy

(Intern Med 57: 681-685, 2018)
(DOI: 10.2169/internalmedicine.9271-17)

Introduction
An accessory spleen (AS) is a common congenital anomaly which is sometimes detected incidentally. It is present in 10-15% of the general population; in about 16% of cases, the AS is located in the pancreas (1, 2). An intrapancreatic AS has the appearance of a hypervascular and solitary lesion. The differential diagnoses include neuroendocrine neoplasms, metastatic tumors, and solid pseudopapillary tumors (3, 4). It is difficult to diagnose an intrapancreatic AS because it sometimes shows uncharacteristic imaging findings. We herein report a rare case involving an intrapancreatic AS that was difficult to distinguish from pancreatic cancer.

Case Report
A 62-year-old man was diagnosed with a pancreatic tumor that was detected by contrast-enhanced computed tomography (CECT). He had undergone hepatic resection and splenectomy for hepatocellular carcinoma and hypersplenism one year previously. The tumor was described as a 2-cm hypovascular mass that had slowly grown after the previous surgeries (Fig. 1, 2). In the arterial phase, the tumor was visualized as a hypovascular lesion on the pancreatic parenchyma, and the imaging effect did not change until the equilibrium phase (Fig. 1). The tumor had been observed as an intrapancreatic AS since before splenectomy, because its imaging characteristics were typical of AS, including hypervascularity, small size, and a circular lesion. It had undergone gradual growth and the hemodynamics had changed from hypervascular to hypovascular (Fig. 2). On magnetic resonance imaging (MRI), the tumor showed low signal intensity on T1-weighted images, faintly high signal intensity on T2-weighted images, high signal intensity on diffusion-weighted MRI, and a low signal intensity on an apparent diffusion coefficient (ADC) map (Fig. 3). No uptake was observed on positron emission tomography imaging CT (PET/CT) (Fig. 4). The laboratory data on admission showed that the patient’s carcinoembryonic antigen (CEA) level was elevated (Table). We could not deny pancreatic cancer in view of the course. Then, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was performed. The tumor was visualized as a low echoic lesion without cystic change by EUS. EUS-FNA revealed the presence of lymphocytes (Fig. 5); however, immunohistochemical staining revealed that the cells were negative for CD8. Thus, $^{99m}$Tc sulfur colloid scintigraphy was performed to differentiate the tumor as a malignant tumor and the uptake of the tracer was observed within the mass (Fig. 6). These results indicated that the tumor was an intrapancreatic AS with...
Figure 1. CECT showed a hypovascular tumor in the pancreatic tail (yellow circle). The tumor was visualized as a hypovascular lesion on the pancreatic parenchyma, and the imaging effect did not change from the arterial phase to the equilibrium phase. CECT: contrast-enhanced computed tomography.

Figure 2. A series of arterial-phase CT images. The tumor (yellow circle) grew slowly and the hemodynamics changed from hypervascular to hypovascular after splenectomy.

compensatory growth after splenectomy. The patient was followed closely without treatment, and the tumor has shown no change after one year.

Discussion

An AS is a common congenital anomaly, and an intrapancreatic AS can be confusing to diagnose because it takes various forms; it sometimes appears similar to a pancreatic neoplasm (5-7). It is widely known that epidermoid cysts may arise in association with an intrapancreatic AS; however, in the present case, a growing tumor was detected in the pancreatic tail, and the hemodynamic changes in the tumor vessels developed during follow-up. An AS generally tends to be a hypervascular lesion, but the tumor was a hypovascular lesion without a cystic lesion that could be detected by MRI, and which showed slow growth. Additionally, the elevated CEA level complicated the diagnosis. Previous studies have reported the utility of EUS-FNA in the diagnosis of an AS (7, 8); we also performed EUS-FNA to make a definitive diagnosis. EUS-FNA revealed that it was a lymphocyte-rich tumor, but did not detect CD8-positive cells, which prove the presence of endothelial cells of the splenic sinus. ⁹⁹mTc sulfur colloid scintigraphy has also been reported to be effective for differentiating tumors from an AS (9). In this case, the uptake of ⁹⁹mTc by the tumor was detected, and we concluded that the tumor was actually an AS. Some studies have reported the compensated growth of an AS after splenectomy; we therefore considered that the imaging findings of this tumor were caused by hemodynamic changes that occurred due to splenectomy (10, 11). However, the reason for the hypovascular change remains unclear. We suspected that epidermoid cysts arose from the AS; however, no cystic lesions were detected by MRI or EUS. The patient was followed for one year without significant changes. These findings suggest that an AS can turn grow and change from hypervascular to hypovascular after splenectomy, and a careful diagnosis must be made using various diagnostic methods.
Figure 3. MRI showed a nodule with low signal intensity on T1-weighted images and faintly high signal intensity on T2-weighted images (yellow circle).

Figure 4. A PET/CT image; no abnormal uptake was observed in the tumor at 90 minutes after the administration of FDG (yellow circle). PET/CT: positron emission tomography imaging CT, FDG: fluorodeoxyglucose
**Table.** Laboratory Data on Admission.

<table>
<thead>
<tr>
<th>Blood count</th>
<th>AST 32 IU/L</th>
<th>Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC 7.97 ×10^9/μL</td>
<td>ALT 25 IU/L</td>
<td>HBs Ag (-)</td>
</tr>
<tr>
<td>RBC 2.98 ×10^12/μL</td>
<td>ALP 438 IU/L</td>
<td>HBs Ab (-)</td>
</tr>
<tr>
<td>Ht 28.1 %</td>
<td>γGTP 41 IU/L</td>
<td>HCV Ab (-)</td>
</tr>
<tr>
<td>Hb 8.8 g/dL</td>
<td>ChE 186 IU/L</td>
<td></td>
</tr>
<tr>
<td>Plt 33.9 ×10^3/μL</td>
<td>LDH 225 IU/L</td>
<td>Tumor marker</td>
</tr>
<tr>
<td>Cr 0.77 mg/dL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Chemistry**

| TP 7.3 g/dL | Na 138 mEq/L | CEA 14.6 ng/mL |
| Alb 3.9 g/dL | K 4.3 mEq/L | |
| T-Bil 0.65 mg/dL | Cl 106 mEq/L | DUPAN-2 82 U/mL |
| D-Bil 0.12 mg/dL | CRP 0.5 mg/dL | SPAN-1 <10 ng/mL |
| BUN 8.3 mg/dL | PIVKA-2 2.6 mAU/mL |


**Figure 5.** Left: A low echoic lesion of 2 cm in length in the pancreatic tail was detected by EUS (yellow circle). The lesion did not include a cystic lesion. It was punctured with a 22-gauge needle and tumor tissue was collected. Right: Hematoxylin and Eosin staining showed lymphocytes, as is observed in splenic tissue. EUS: endoscopic ultrasound, EUS-FNA: endoscopic ultrasound-guided fine-needle aspiration.

**Figure 6.** ⁹⁹mTc sulfur colloid scintigraphy showed a high uptake into the tumor of the pancreatic tail (yellow circle).
The authors state that they have no Conflict of Interest (COI).

References